Zymeworks (ZYME) Misses Q4 EPS, Revenue Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results
March 7, 2023 4:05 PM EST2022 was a year of transformation and change: reported $412.5 million in total revenue for the year ended December 31, 2022; reported net income of $124.3 million ($1.90 per fully diluted share) for 2022 compared to net loss of $211.8 million in 2021; reported $492.2 million in cash resources as of December 31, 2022, with expected cash runway through 2026; announced positive top-line data for pivotal Phase 2 study of zanidatamab monotherapy in 2L+ patients with HER2-amplified advanced biliary tract cancers (BTC); presented updated results at ASCO GI, including overall survival data, for ongoing Phase 2 study of zanidatamab in 1L... More
